4,058 reports of this reaction
3.7% of all DABIGATRAN ETEXILATE reports
#2 most reported adverse reaction
CEREBROVASCULAR ACCIDENT is the #2 most commonly reported adverse reaction for DABIGATRAN ETEXILATE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 4,058 FDA adverse event reports linking DABIGATRAN ETEXILATE to CEREBROVASCULAR ACCIDENT. This represents approximately 3.7% of all 111,048 adverse event reports for this drug.
Patients taking DABIGATRAN ETEXILATE who experience cerebrovascular accident should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CEREBROVASCULAR ACCIDENT is moderately reported among DABIGATRAN ETEXILATE users, representing a notable but not dominant share of adverse events.
In addition to cerebrovascular accident, the following adverse reactions have been reported for DABIGATRAN ETEXILATE:
The following drugs have also been linked to cerebrovascular accident in FDA adverse event reports:
CEREBROVASCULAR ACCIDENT has been reported as an adverse event in 4,058 FDA reports for DABIGATRAN ETEXILATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CEREBROVASCULAR ACCIDENT accounts for approximately 3.7% of all adverse event reports for DABIGATRAN ETEXILATE, making it one of the most commonly reported side effect.
If you experience cerebrovascular accident while taking DABIGATRAN ETEXILATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.